{"ticker": {"uuid": "11ec5f36-eff4-4b5e-be2f-2a6e445d852d", "symbol": "NSIS-B", "name": "Novozymes A/S", "exchange": "CPH", "country": "DK", "sector": "Basic Materials", "industry": "Specialty Chemicals"}, "articles": [{"title": "Novozymes (CPSE:NSIS B) Stock Could Be 31% Below Fair Value After UndoAge Deal", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Novozymes (CPSE:NSIS B) Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQR05yME1GUWQtbnlHMTVkb2lEMEhXSHdrYTFUTzR5V0FDYURkZktCRUZtX1I2ZkpBR0NkeDdPeDJaWi1sR3F4aW8zbWxBcnlBVTNmTGVwcFFPeGhETVJpUzVpZzNKeWtTbUR0ZHZNcTYwVjh4bDZRRkdCMHlEV21uRlljb2lrdDU0YWFHRU5GUHE5bjhNbkE?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novozymes and Chr. Hansen Complete Merger, Forming Novonesis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOVjMzVFJrcDF4Ny1ucEd3aEk1bVE2X0Y2MFAzWktNdktYU1dQVEJic1p6ZHBjLUxsMkhzMkhMVC1MSU94RGpyQmxVeG1sdjhGbUZzOFF4b3c5c2ZmMmtMYU8xS0lod0tqLXVObHdpaUdQeU9UTXhXY3V1VWRSWGZ6YmRqQU9NWXU3N295TGI5UWh3ZkhMSWlRcXR0ME40N3ppMTJzb2l2djViUQ?oc=5", "source_name": "European Biotechnology Magazine", "published_at": "2024-01-29T08:00:00+00:00", "published_display": "29 Jan 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novozymes Agrees to Buy Chr. Hansen in $12.3 Billion Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOVzNaTUZ0UlBQYzZDQU9QTW1VbzVtOHJmT1pjWkpaVG9PU1RfN1lwZGk1S01KNk0xQmg1dktUUTJ1M2pjNDI3WDZCcng4YzVzSWI4aHNiV2xWN1FSUXU0NGFWbVRwODBVbXYwdnB3NUp4TnhuTWxJemhocTZqVlBteURlQ1V0Y0twSm1aTWQ5RGk4UE1kZkxZWktFWXA0LWhUTk45N01zTjdOQQ?oc=5", "source_name": "Bloomberg.com", "published_at": "2022-12-12T08:00:00+00:00", "published_display": "12 Dec 2022 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Novozymes (CPSE:NSIS B) Stock Could Be 31% Below Fair Value After UndoAge Deal", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Novozymes (CPSE:NSIS B) Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQR05yME1GUWQtbnlHMTVkb2lEMEhXSHdrYTFUTzR5V0FDYURkZktCRUZtX1I2ZkpBR0NkeDdPeDJaWi1sR3F4aW8zbWxBcnlBVTNmTGVwcFFPeGhETVJpUzVpZzNKeWtTbUR0ZHZNcTYwVjh4bDZRRkdCMHlEV21uRlljb2lrdDU0YWFHRU5GUHE5bjhNbkE?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novozymes and Chr. Hansen Complete Merger, Forming Novonesis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOVjMzVFJrcDF4Ny1ucEd3aEk1bVE2X0Y2MFAzWktNdktYU1dQVEJic1p6ZHBjLUxsMkhzMkhMVC1MSU94RGpyQmxVeG1sdjhGbUZzOFF4b3c5c2ZmMmtMYU8xS0lod0tqLXVObHdpaUdQeU9UTXhXY3V1VWRSWGZ6YmRqQU9NWXU3N295TGI5UWh3ZkhMSWlRcXR0ME40N3ppMTJzb2l2djViUQ?oc=5", "source_name": "European Biotechnology Magazine", "published_at": "2024-01-29T08:00:00+00:00", "published_display": "29 Jan 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novozymes Agrees to Buy Chr. Hansen in $12.3 Billion Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOVzNaTUZ0UlBQYzZDQU9QTW1VbzVtOHJmT1pjWkpaVG9PU1RfN1lwZGk1S01KNk0xQmg1dktUUTJ1M2pjNDI3WDZCcng4YzVzSWI4aHNiV2xWN1FSUXU0NGFWbVRwODBVbXYwdnB3NUp4TnhuTWxJemhocTZqVlBteURlQ1V0Y0twSm1aTWQ5RGk4UE1kZkxZWktFWXA0LWhUTk45N01zTjdOQQ?oc=5", "source_name": "Bloomberg.com", "published_at": "2022-12-12T08:00:00+00:00", "published_display": "12 Dec 2022 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 74, "total_relevant": 4, "sentiment_summary": {"positive": 1, "negative": 0, "neutral": 3, "score": 56, "total": 4, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "deals", "primary_label": "Deals and strategy", "confidence": 72, "events": [{"event": "deals", "label": "Deals and strategy", "weight": 2.0, "count": 3}, {"event": "general", "label": "Market update", "weight": 0.55, "count": 1}], "positive_events": 1, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 424.5, "latest_week": "2026-07-17", "one_week_move": -0.1, "four_week_move": 7.7, "twelve_week_move": 10.5, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.402872, "market_dynamics_buy_signal": false, "relative_strength": -1.457113, "fair_value_gap": 7.8, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 47.2539, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.1% over one week, +7.7% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 52, "badges": [], "opportunities": [], "risks": [], "event_label": "Deals and strategy", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "simplywall.st", "count": 1}, {"label": "Market source", "count": 1}, {"label": "European Biotechnology Magazine", "count": 1}, {"label": "Bloomberg.com", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 4}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Deals and strategy", "count": 3}, {"label": "Market update", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Deals and strategy", "tone": "neutral", "text": "72/100 classification confidence."}, {"label": "Company focus", "value": "4", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-0.1% over one week, +7.7% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Novozymes (CPSE:NSIS B) Stock Could Be 31% Below Fair Value After UndoAge Deal"}], "updated_at": "2026-07-18T14:56:58.104121+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}